Fibrosis, Liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In patients with nonalcoholic steatohepatitis (NASH), PNPLA3 GG compared to CC was associated with higher AST levels [38.4±25.3 versus 36.7±40.1IU/L, p=0.0395)] and with the presence of liver fibrosis (≥F2 fibrosis, p=0.0272).
|
31054980 |
2020 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In multivariate models adjusting for histologic features of nonalcoholic steatohepatitis and liver fibrosis, PNPLA3 I148M is associated with a decrease in VLDL particle size.
|
28362682 |
2019 |
Fibrosis, Liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PNPLA3 G was also associated with increased levels of ALT, except in participants with Dominican and South American backgrounds, and with liver fibrosis.
|
30743004 |
2019 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multiple logistic regression was performed to investigate the association of PNPLA3 G allele with clinical and laboratory variables and with hepatic fibrosis/steatosis.
|
31377187 |
2019 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study aims to assess the impact of IL28B rs8099917 polymorphism on CHC genotype 4 (G4) susceptibility and liver fibrosis progression individually; and in combination with PNPLA3 rs738409.<b>Patients and methods:</b> IL28B rs8099917 and PNPLA3 rs738409 were genotyped in 150 Egyptian CHC patients and 175 healthy controls using real-time PCR.<b>Results:</b> IL28B rs8099917 genotype distribution significantly differs in healthy individuals versus CHC patients (<i>p</i> = .018); and in low versus advanced fibrosis IL28B (<i>p</i> = .013).
|
31793339 |
2019 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
These genetic variations also did not mediate the effect of <i>PNPLA3 rs738409</i> SNP for liver developing liver fibrosis or liver cirrhosis.
|
30875804 |
2019 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The rs738409 C>G p.I148M variant in the patatin-like phospholipase domain containing 3 (PNPLA3)-gene promotes triglyceride accumulation in hepatocytes and hepatic stellate cell activation and has previously been linked to hepatic steatosis/liver fibrosis.
|
29956823 |
2018 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409 polymorphism appears to be related to the increased progression of liver fibrosis in HCV infected patients.
|
29674183 |
2018 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The Association of PNPLA3, COX-2 and DHCR7 Polymorphisms with Advanced Liver Fibrosis in Patients with HCV Mono- Infection and HCV/HIV Co-Infection
|
30139224 |
2018 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using a newly developed and validated assay for PNPLA3, we explored the prevalence of gene polymorphisms in a cohort of HCV/HIV-coinfected individuals to determine whether there was an association with insulin resistance or hepatic fibrosis.
|
30218427 |
2018 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Presence of minor allele (G) of PNPLA3 was also associated with moderate/severe steatosis (≥33%) both in patients with (OR: 2.405 [CI95%: 1.220-4.744], P=0.011) and without MetS (OR: 2.481 [CI95%: 1.172-5.250], P=0.018), but was only associated with NASH (OR: 2.002 [CI95%: 1.062-3.772], P=0.032) and liver fibrosis (OR: 2.646 [CI95%: 1.299-5.389], P=0.007) in patients without MetS.
|
27908400 |
2017 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 genotypes were also associated with higher risk of developing liver fibrosis and cirrhosis in dominant (aOR: 1.98, P=2.20*10-5; aOR: 1.67, P=0.008, respectively) and recessive (aOR: 3.94, P=5.16*10-5; aOR: 3.02, P=0.003, respectively) models.
|
28338112 |
2017 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study assessed the contribution of the PNPLA3 rs738409 polymorphism with regard to the steatosis and degree of liver fibrosis in Brazilian patients diagnosed with chronic hepatitis C.
|
29258449 |
2017 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fetuin B is independently and negatively associated with non-invasive markers of liver fibrosis and PNPLA3 status in NAFLD patients but does not show a correlation with the hepatic lipid content.
|
28914407 |
2017 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409 G allele carriers were found to be more susceptible to the metabolic-related hepatic steatosis, and developed NAFLD and liver fibrosis despite presenting relatively better metabolic statuses and lower risks for carotid atherosclerosis.
|
26765961 |
2016 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Contradictory data about the impact of the rs738409 steatosis-related polymorphism within PNPLA3 gene on liver fibrosis progression in HIV/hepatitis C virus (HIV/HCV)-coinfected patients have been reported.
|
27973562 |
2016 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409 polymorphism was associated with the severity of liver fibrosis in patients coinfected with HIV and hepatitis C virus, suggesting that this polymorphism might also play a significant role in the progression of hepatic fibrosis in this group of patients.
|
26760234 |
2016 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409 (C>G) was associated with the risk of both advanced liver fibrosis and steatosis in patients with CHC, especially among Caucasian populations.
|
26419236 |
2016 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, we provide evidence to indicate that PNPLA3-mediated retinol release may protect against liver fibrosis by inducing a specific signature of proteins involved in extracellular matrix remodelling.
|
27742777 |
2016 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Finally, we briefly highlight future research that may elucidate the specific mechanisms of the PNPLA3 I148M variant in fibrogenesis, which, in turn, provides a theoretical foundation and valuable experimental data for the clinical management of nonalcoholic fatty liver fibrosis.
|
25624712 |
2015 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To perform a comprehensive study on independent modulators of liver fibrosis progression and determinants of portal pressure considering immune status, insulin resistance (IR), serum 25-hydroxyvitamin D (25(OH)D) levels, genetic variants of patatin-like phospholipase domain-containing protein 3 (PNPLA3) and interleukin 28B (IL28B) in a thoroughly documented cohort of HIV/hepatitis C-coinfected (HIV/HCV) patients.
|
24905495 |
2015 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
When patients were grouped according to their diabetes status, the PNPLA3 genetic variants were associated with advanced liver fibrosis in diabetic patients only, but not in non-diabetic patients.
|
25457210 |
2015 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In patients with both CHB and NAFLD, these genotypes of PNPLA3 polymorphisms were associated with increased susceptibility to nonalcoholic steatohepatitis (NASH) (NAFLD activity score ≥ 3; P = 0.01-0.03) and liver fibrosis (> 1 Metavir grading; P = 0.01-0.04).
|
26229402 |
2015 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Advanced liver fibrosis was neither associated with PNPLA3 (p = 0.253) nor IL28B-genotype (p = 0.628), but with HCV-GT3 (p = 0.003), higher BMI (p = 0.008) and higher age (p = 0.007).
|
26599080 |
2015 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A genetic variant in adiponutrin (PNPLA3) gene, rs738409 C/G, is associated with steatosis, severity, and progression of liver fibrosis in CHC patients, and predicts treatment outcome in difficult-to-cure HCV-infected patients with advanced fibrosis.
|
26389885 |
2015 |